Joseph Michael Collaco

Joseph Michael Collaco

Auto-generated profile, based on publicly available information

Joseph Michael Collaco

Johns Hopkins Medical Institutions Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Pediatrics in Review
Verified
Journal Article
Closed access
PDF file
KDKimberly M. Dickinson
Kimberly M. Dickinson
JCJoseph M. Collaco
Joseph M. Collaco
Cystic fibrosis (CF) is one of the most commonly diagnosed genetic disorders. Clinical characteristics include progressive obstructive lung disease, sinusitis, exocrine pancreatic insufficiency leading to malabsorption and malnutrition, liver and pancreatic dysfunction, and male infertility. Although CF is a life-shortening disease, survival has continued to improve to a median age of 46.2 years due to earlier diagnosis through routine newborn screening, promulgation of evidence-based guidelines to optimize nutritional and pulmonary health, and the development of CF-specific interdisciplinary care centers. Future improvements in health and quality of life for individuals with CF are likely with the recent development of mutation-specific modulator therapies. In this review, we will cover the current understanding of the disease manifestations, diagnosis, and management as well as common complications seen in individuals with CF.

1 May 2018 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
JCJoseph M. Collaco
Joseph M. Collaco
SMSharon A. McGrath-Morrow
Sharon A. McGrath-Morrow
Ongoing advancements in neonatal care since the late 1980s have led to increased numbers of premature infants surviving well beyond the neonatal period. As a result of increased survival, many individuals born preterm manifest chronic respiratory symptoms throughout infancy, childhood, and adult life. The archetypical respiratory disease of prematurity, bronchopulmonary dysplasia, is the second most common chronic pediatric respiratory disease after asthma. However, there are several commonly held misconceptions. These misconceptions include that bronchopulmonary dysplasia is rare, that bronchopulmonary dysplasia resolves within the first few years of life, and that bronchopulmonary dysplasia does not impact respiratory health in adult life. This focused review describes a spectrum of respiratory conditions that individuals born prematurely may experience throughout their lifespan. Specifically, this review provides quantitative estimates of the number of individuals with alveolar, airway, and vascular phenotypes associated with bronchopulmonary dysplasia, as well as non-bronchopulmonary dysplasia respiratory phenotypes such as airway malacia, obstructive sleep apnea, and control of breathing issues. Furthermore, this review illustrates what is known about the potential for progression and/or lack of resolution of these respiratory phenotypes in childhood and adult life. Recognizing the spectrum of respiratory phenotypes associated with individuals born preterm and providing comprehensive and personalized care to these individuals may help to modulate adverse respiratory outcomes in later life.

18 November 2011 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJoseph M. Collaco
Joseph M. Collaco
JMJohn McGready
John McGready
DGDeanna M. Green
Deanna M. Green
KNKathleen M. Naughton
Kathleen M. Naughton
CWChristopher P. Watson
Christopher P. Watson
CWClaire E. Wainwright
Claire E. Wainwright
Progressive lung disease accounts for the majority of morbidity and mortality observed in cystic fibrosis (CF). Beyond secondhand smoke exposure and socio-economic status, the effect of specific environmental factors on CF lung function is largely unknown. Multivariate regression was used to assess correlation between specific environmental factors, the presence of pulmonary pathogens, and variation in lung function using subjects enrolled in the U.S. CF Twin and Sibling Study (CFTSS: n = 1378). Significant associations were tested for replication in the U.S. CF Foundation Patient Registry (CFF: n = 16439), the Australian CF Data Registry (ACFDR: n = 1801), and prospectively ascertained subjects from Australia/New Zealand (ACFBAL: n = 167). In CFTSS subjects, the presence of Pseudomonas aeruginosa (OR = 1.06 per °F; p<0.001) was associated with warmer annual ambient temperatures. This finding was independently replicated in the CFF (1.02; p<0.001), ACFDR (1.05; p = 0.002), and ACFBAL (1.09; p = 0.003) subjects. Warmer temperatures (−0.34 points per °F; p = 0.005) and public insurance (−6.43 points; p<0.001) were associated with lower lung function in the CFTSS subjects. These findings were replicated in the CFF subjects (temperature: −0.31; p<0.001; insurance: −9.11; p<0.001) and similar in the ACFDR subjects (temperature: −0.23; p = 0.057). The association between temperature and lung function was minimally influenced by P. aeruginosa. Similarly, the association between temperature and P. aeruginosa was largely independent of lung function. Ambient temperature is associated with prevalence of P. aeruginosa and lung function in four independent samples of CF patients from two continents.

1 November 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JCJ. Michael Collaco
J. Michael Collaco
DGDeanna M. Green
Deanna M. Green
GCGarry R. Cutting
Garry R. Cutting
KNKathleen M. Naughton
Kathleen M. Naughton
PMPeter J. Mogayzel
Peter J. Mogayzel
Rationale: Individuals with cystic fibrosis (CF) are subject to recurrent respiratory infections (exacerbations) that often require intravenous antibiotic treatment and may result in permanent loss of lung function. The optimal means of delivering therapy remains unclear. Objectives: To determine whether duration or venue of intravenous antibiotic administration affect lung function. Methods: Data were retrospectively collected on 1,535 subjects recruited by the US CF Twin and Sibling Study from US CF care centers between 2000 and 2007. Measurements and Main Results: Long-term decline in FEV1 after exacerbation was observed regardless of whether antibiotics were administered in the hospital (mean, −3.3 percentage points [95% confidence interval, −3.9 to −2.6]; n = 602 courses of therapy) or at home (mean, −3.5 percentage points [95% confidence interval, −4.5 to −2.5]; n = 232 courses of therapy); this decline was not different by venue using t tests (P = 0.69) or regression (P = 0.91). No difference in intervals between courses of antibiotics was observed between hospital (median, 119 d [interquartile range, 166]; n = 602) and home (median, 98 d [interquartile range, 155]; n = 232) (P = 0.29). Patients with greater drops in FEV1 with exacerbations had worse long-term decline even if lung function initially recovered with treatment (P < 0.001). Examination of FEV1 measures obtained during treatment for exacerbations indicated that improvement in FEV1 plateaus after 7–10 days of therapy. Conclusions: Intravenous antibiotic therapy for CF respiratory exacerbations administered in the hospital and in the home was found to be equivalent in terms of long-term FEV1 change and interval between courses of antibiotics. Optimal duration of therapy (7–10 d) may be shorter than current practice. Large prospective studies are needed to answer these essential questions for CF respiratory management.

1 December 2016 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
JCJoseph M. Collaco
Joseph M. Collaco
SBScott M. Blackman
Scott M. Blackman
KRKaren S. Raraigh
Karen S. Raraigh
HCHarriet Corvol
Harriet Corvol
JRJohanna M. Rommens
Johanna M. Rommens
GCGarry R. Cutting
Garry R. Cutting
Rationale: Expanding the use of cystic fibrosis transmembrane conductance regulator (CFTR) potentiators and correctors for the treatment of cystic fibrosis (CF) requires precise and accurate biomarkers. Sweat chloride concentration provides an in vivo assessment of CFTR function, but it is unknown the degree to which CFTR mutations account for sweat chloride variation. Objectives: To estimate potential sources of variation for sweat chloride measurements, including demographic factors, testing variability, recording biases, and CFTR genotype itself. Methods: A total of 2,639 sweat chloride measurements were obtained in 1,761 twins/siblings from the CF Twin-Sibling Study, French CF Modifier Gene Study, and Canadian Consortium for Genetic Studies. Variance component estimation was performed by nested mixed modeling. Measurements and Main Results: Across the tested CF population as a whole, CFTR gene mutations were found to be the primary determinant of sweat chloride variability (56.1% of variation) with contributions from variation over time (e.g., factors related to testing on different days; 13.8%), environmental factors (e.g., climate, family diet; 13.5%), other residual factors (e.g., test variability; 9.9%), and unique individual factors (e.g., modifier genes, unique exposures; 6.8%) (likelihood ratio test, P < 0.001). Twin analysis suggested that modifier genes did not play a significant role because the heritability estimate was negligible (H2 = 0; 95% confidence interval, 0.0–0.35). For an individual with CF, variation in sweat chloride was primarily caused by variation over time (58.1%) with the remainder attributable to residual/random factors (41.9%). Conclusions: Variation in the CFTR gene is the predominant cause of sweat chloride variation; most of the non-CFTR variation is caused by testing variability and unique environmental factors. If test precision and accuracy can be improved, sweat chloride measurement could be a valuable biomarker for assessing response to therapies directed at mutant CFTR.

1 February 2015 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
JCJoseph M. Collaco
Joseph M. Collaco
AAAngela D. Aherrera
Angela D. Aherrera
KYKarla J. Au Yeung
Karla J. Au Yeung
MLMaureen A. Lefton-Greif
Maureen A. Lefton-Greif
JHJeannine Hoch
Jeannine Hoch
MSMargaret L. Skinner
Margaret L. Skinner
Children with complex respiratory and gastrointestinal symptoms, also known as aerodigestive disorders, can present with a variety of diagnoses, including sleep apnea, asthma, congenital airway or esophageal anomalies, dysphagia, feeding disorders, gastroesophageal reflux, esophagitis, and/or airway malacia. The burden of disease is unknown because no estimates of the prevalence of these complex aerodigestive disorders exist, but these conditions may be more common than previously realized. One common presentation of a pediatric aerodigestive disorder is infant feeding disorder: in 2010 2.6% of sick newborns discharged from short hospital stays in the United States had feeding disorders (International Classification of Diseases, Ninth Revision [ICD-9] code 779.3).1 These disorders, even as comorbidities, can lead to increased mortality and morbidity; for example, comorbid dysphagia in hospitalized patients has been associated with longer hospital stays and increased mortality.2 These children frequently require care from multiple pediatric subspecialists, including gastroenterologists, dietitians and/or nutritionists, otolaryngologists, pulmonologists, respiratory therapists, and speech-language pathologists. Over the past decade, a number of pediatric tertiary care hospitals have established interdisciplinary clinics to coordinate care,3,4 including at least 35 centers in the United States as of May 2014 (found via systematic web search for pediatric aerodigestive center websites, May 16, 2014).